Meridian Inks Deal with Premier to Offer illumigene Molecular Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience announced after the close of the market on Thursday that it has reached an agreement with Premier healthcare alliance to offer members of the alliance Meridian's illumigene C. difficile and illumigene Group B Streptococcus molecular tests.

Meridian will offer the two tests to the 2,500 US hospitals and more than 81,000 other healthcare sites that are part of Premier at specially negotiated prices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.